Eyenuk, Inc. Expands into Germany with Launch of EyeArt® Artificial Intelligence Eye Screening for Diabetic Retinopathy

Diabetes Center Mergentheim is the First in Germany to Use AI for Real-Time, In-Clinic Eye Screening for This Blinding Disease.

LOS ANGELES--(BUSINESS WIRE)--Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults(1).